Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 26 02 2021
accepted: 19 03 2021
pubmed: 30 3 2021
medline: 25 11 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

Among four sub-patterns of Gleason grade 4 prostate cancer, voluminous evidence supports that the cribriform pattern holds an unfavorable prognostic impact, as compared with poorly-formed, fused, or glomeruloid. The International Society of Urological Pathology (ISUP) recommends specifying whether invasive grade 4 cancer is cribriform. Recently, ISUP experts published a consensus definition of cribriform pattern highlighting criteria that distinguish it from mimickers. The current study aimed to analyze morphologic features separately to identify those that define the essence of the cribriform pattern. Thirty-two selected photomicrographs were classified by 12 urologic pathologists as: definitely cribriform cancer, probably cribriform, unsure, probably not cribriform, or definitely not cribriform. Consensus was defined as 9/12 agree or disagree, with ≤1 strongly supporting the opposite choice. Final consensus was achieved in 21 of 32 cases. Generalized estimating equation (GEE) model with logit link was fitted to estimate effect of multiple morphologic predictors. Fisher exact test was used for categorical findings. Presence of intervening stroma precluded calling cribriform cancer (p = 0.006). Mucin presence detracted (p = 0.003) from willingness to call cribriform cancer (only 3 cases had mucin). Lumen number was associated with cribriform consensus (p = 0.0006), and all consensus cases had ≥9 lumens. Predominant papillary pattern or an irregular outer boundary detracted (p = NS). Invasive cribriform carcinoma should have absence of intervening stroma, and usually neither papillary pattern, irregular outer boundary, nor very few lumens. Setting the criteria for cribriform will help prevent over- or undercalling this important finding.

Identifiants

pubmed: 33780691
pii: S1092-9134(21)00033-2
doi: 10.1016/j.anndiagpath.2021.151733
pii:
doi:

Substances chimiques

Mucins 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151733

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Kenneth A Iczkowski (KA)

Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, United States of America. Electronic address: kaiczkowski@mcw.edu.

Geert J L H van Leenders (GJLH)

Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

Sergey Tarima (S)

Department of Biostatistics and Ethics, Medical College of Wisconsin, Milwaukee, WI, United States of America.

Ruizhe Wu (R)

Department of Biostatistics and Ethics, Medical College of Wisconsin, Milwaukee, WI, United States of America.

Theodorus Van der Kwast (T)

Dept. of Pathology, Toronto General Hospital, Toronto, Canada.

Daniel M Berney (DM)

Department of Pathology, Barts Health NHS TRUST, London, United Kingdom.

Andrew J Evans (AJ)

Department of Pathology, Mackenzie Health, Richmond Hill, Ontario, Canada.

Thomas M Wheeler (TM)

Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, United States of America.

Jae Y Ro (JY)

Department of Pathology & Genomic Medicine, Houston Methodist Hospital, Weill Medical College, Cornell University, Houston, TX, United States of America.

Hemamali Samaratunga (H)

Department of Pathology, University of Queensland School of Medicine, Aquesta Uropathology, Queensland, Australia.

Brett Delahunt (B)

Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.

John Srigley (J)

Trillium Health Partners Mississauga, Ontario, Canada.

Murali Varma (M)

Department of Cellular Pathology, University Hospital of Wales, Cardiff, Wales, United Kingdom.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University Hospital, Japan.

Lars Egevad (L)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH